Company intelligence / Profile preview

Vitaeris Inc.

Vancouver, British Columbia, Canadaoxyhealth.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

The company's lead product clazakizumab was in Phase III development for treating rejection in solid organ kidney transplant patients. A February 2023 study showed accumulation of antibody-neutralized interleukin-6 without signs of proinflammatory rebound phenomena in antibody-mediated renal allograft rejection[2].

Therapeutic areas: Nephrology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

clazakizumab

Phase 3

Indications: Chronic active antibody-mediated rejection, Kidney transplant rejection

Partnerships

Strategic partnership with CSL Limited formed in 2017, which later led to acquisition

Beyond the preview

Go deeper on Vitaeris Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitaeris Inc..

Explore the full profile